195 related articles for article (PubMed ID: 25618774)
1. Molecular drivers of cellular metabolic reprogramming in melanoma.
Abildgaard C; Guldberg P
Trends Mol Med; 2015 Mar; 21(3):164-71. PubMed ID: 25618774
[TBL] [Abstract][Full Text] [Related]
2. Targeting metabolic reprogramming as a potential therapeutic strategy in melanoma.
Smith LK; Rao AD; McArthur GA
Pharmacol Res; 2016 May; 107():42-47. PubMed ID: 26924126
[TBL] [Abstract][Full Text] [Related]
3. Inactivation of the HIF-1α/PDK3 signaling axis drives melanoma toward mitochondrial oxidative metabolism and potentiates the therapeutic activity of pro-oxidants.
Kluza J; Corazao-Rozas P; Touil Y; Jendoubi M; Maire C; Guerreschi P; Jonneaux A; Ballot C; Balayssac S; Valable S; Corroyer-Dulmont A; Bernaudin M; Malet-Martino M; de Lassalle EM; Maboudou P; Formstecher P; Polakowska R; Mortier L; Marchetti P
Cancer Res; 2012 Oct; 72(19):5035-47. PubMed ID: 22865452
[TBL] [Abstract][Full Text] [Related]
4. RSK Regulates PFK-2 Activity to Promote Metabolic Rewiring in Melanoma.
Houles T; Gravel SP; Lavoie G; Shin S; Savall M; Méant A; Grondin B; Gaboury L; Yoon SO; St-Pierre J; Roux PP
Cancer Res; 2018 May; 78(9):2191-2204. PubMed ID: 29440170
[TBL] [Abstract][Full Text] [Related]
5. Metabolic reprogramming of metastatic breast cancer and melanoma by let-7a microRNA.
Serguienko A; Grad I; Wennerstrøm AB; Meza-Zepeda LA; Thiede B; Stratford EW; Myklebost O; Munthe E
Oncotarget; 2015 Feb; 6(4):2451-65. PubMed ID: 25669981
[TBL] [Abstract][Full Text] [Related]
6. BRAF in melanoma: current strategies and future directions.
Salama AK; Flaherty KT
Clin Cancer Res; 2013 Aug; 19(16):4326-34. PubMed ID: 23770823
[TBL] [Abstract][Full Text] [Related]
7. Targeting BRAF in melanoma: biological and clinical challenges.
Mandalà M; Voit C
Crit Rev Oncol Hematol; 2013 Sep; 87(3):239-55. PubMed ID: 23415641
[TBL] [Abstract][Full Text] [Related]
8. Perturbation of mitochondrial bioenergetics by polycations counteracts resistance to BRAF
Hall A; Maynard S; Wu LP; Merchut-Maya JM; Strauss R; Moghimi SM; Bartek J
J Control Release; 2019 Sep; 309():158-172. PubMed ID: 31348978
[TBL] [Abstract][Full Text] [Related]
9. Molecular pathways: BRAF induces bioenergetic adaptation by attenuating oxidative phosphorylation.
Haq R; Fisher DE; Widlund HR
Clin Cancer Res; 2014 May; 20(9):2257-63. PubMed ID: 24610826
[TBL] [Abstract][Full Text] [Related]
10. A new standard of care for metastatic melanoma?
Sharma SP
Lancet Oncol; 2015 Jan; 16(1):e8. PubMed ID: 25638559
[No Abstract] [Full Text] [Related]
11. Combination of RAF and MEK inhibition for the treatment of BRAF-mutated melanoma: feedback is not encouraged.
Chapman PB; Solit DB; Rosen N
Cancer Cell; 2014 Nov; 26(5):603-4. PubMed ID: 25517746
[TBL] [Abstract][Full Text] [Related]
12. Combination therapy approved for melanoma.
Cancer Discov; 2014 Mar; 4(3):262. PubMed ID: 24596183
[TBL] [Abstract][Full Text] [Related]
13. Taking the stress out of melanoma.
Martin MJ; Carling D; Marais R
Cancer Cell; 2009 Mar; 15(3):163-4. PubMed ID: 19249673
[TBL] [Abstract][Full Text] [Related]
14. BRAF, a target in melanoma: implications for solid tumor drug development.
Flaherty KT; McArthur G
Cancer; 2010 Nov; 116(21):4902-13. PubMed ID: 20629085
[TBL] [Abstract][Full Text] [Related]
15. Drug combos validated in BRAF-mutant melanoma.
Cancer Discov; 2014 Dec; 4(12):1361-2. PubMed ID: 25477091
[TBL] [Abstract][Full Text] [Related]
16. Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study.
Robert C; Dummer R; Gutzmer R; Lorigan P; Kim KB; Nyakas M; Arance A; Liszkay G; Schadendorf D; Cantarini M; Spencer S; Middleton MR
Lancet Oncol; 2013 Jul; 14(8):733-40. PubMed ID: 23735514
[TBL] [Abstract][Full Text] [Related]
17. Towards personalized therapy for patients with malignant melanoma: molecular insights into the biology of BRAF mutations.
Bradish JR; Montironi R; Lopez-Beltran A; Post KM; MacLennan GT; Cheng L
Future Oncol; 2013 Feb; 9(2):245-53. PubMed ID: 23414474
[TBL] [Abstract][Full Text] [Related]
18. Narrative review: BRAF opens the door for therapeutic advances in melanoma.
Flaherty KT
Ann Intern Med; 2010 Nov; 153(9):587-91. PubMed ID: 21041578
[TBL] [Abstract][Full Text] [Related]
19. BRAF inhibitors and melanoma.
Flaherty KT
Cancer J; 2011; 17(6):505-11. PubMed ID: 22157295
[TBL] [Abstract][Full Text] [Related]
20. Glucose-independent Acetate Metabolism Promotes Melanoma Cell Survival and Tumor Growth.
Lakhter AJ; Hamilton J; Konger RL; Brustovetsky N; Broxmeyer HE; Naidu SR
J Biol Chem; 2016 Oct; 291(42):21869-21879. PubMed ID: 27539851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
